Friday, May 1, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Daily Remedy podcast with Aneri Pattani, senior correspondent for KFF Health News

We discuss Miss Pattani’s reporting on opioid settlements, highlighting the advocacy of patients most affected. Through KFF Health News, she leads an initiative to track how opioid settlement funds are allocated.

Miss Aneri Pattani is a national correspondent with KFF Health News, where she reports on a broad range of public health topics, including mental health, substance use, and the health of adolescents and young adults. She is also a fellow at the Bloomberg American Health Initiative.

#opioids #settlements

Relevant articles cited in the podcast include:

https://khn.org/news/article/opioid-drugmakers-settlement-funds-50-billion-dollars-khn-investigation-payback/

https://khn.org/news/article/state-plans-opioid-settlement-funds/

https://khn.org/news/article/rural-america-opioid-settlement-funds-inequity/

https://www.opioidsettlementtracker.com/publicreporting/#promises

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!